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BACKGROUND: After discontinuing ruxolitinib, the outcome of patients with myelofibrosis reportedly has been poor. The authors investi-
gated whether disease characteristics before the receipt of ruxolitinib may predict drug discontinuation in patients with myelofibrosis and 
whether reasons for drug discontinuation, disease phase at discontinuation, and salvage therapies may influence the outcome. METHODS: 
A centralized electronic clinical database was created in 20 European hematology centers, including clinical and laboratory data for 524 
patients who received ruxolitinib for myelofibrosis. RESULTS: At 3 years, 40.8% of patients had stopped ruxolitinib. Baseline predictors 
of drug discontinuation were: intermediate-2–risk/high-risk category (Dynamic International Prognostic Score System), a platelet count 
<100 ×109 per liter, transfusion dependency, and unfavorable karyotype. At last contact, 268 patients (51.1%) had discontinued therapy, 
and the median drug exposure was 17.5 months. Fifty patients (18.7%) died while taking ruxolitinib. The reasons for discontinuation in the 
remaining 218 patients were the lack (22.9%) or loss (11.9%) of a spleen response, ruxolitinib-related adverse events (27.5%), progression 
to blast phase (23.4%), ruxolitinib-unrelated adverse events (9.2%), and allogeneic transplantation during response (5.1%). The median 
survival after ruxolitinib was 13.2 months and was significantly better in the 167 patients who discontinued ruxolitinib in chronic phase 
(27.5 vs 3.9 months for those who discontinued in blast phase; P <  .001). No survival differences were observed among patients who 
discontinued ruxolitinib in chronic phase because of lack of response, loss of response, or ruxolitinib-related adverse events. The use of 
investigational agents and/or ruxolitinib rechallenge were associated with improved outcome. CONCLUSIONS: The survival of patients 
with myelofibrosis after discontinuation of ruxolitinib is poor, particularly for those who discontinue in blast phase. Salvage therapies can 
improve outcome, emphasizing the need for novel therapies. Cancer 2020;126:1243-1252. © 2019 American Cancer Society. 
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INTRODUCTION
Myelofibrosis (MF) is a rare blood cancer with an incidence of approximately 0.6 new cases per 100,000 people per 
year. It is characterized by a chronic and disabling course, leading to death from disease progression, disease-related 
complications, and/or treatment-related complications.1 In MF, hyperactivation of the JAK-STAT pathway induces 
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myeloproliferation and expression of proinflammatory 
cytokines.2 This discovery raised hopes that MF may be 
cured by the use of JAK inhibitors, as in chronic myeloid 
leukemia, which is treated with Bcr-Abl inhibitors3; how-
ever, JAK-inhibitor treatments do not affect disease bur-
den or the JAK-mutated clone to a major extent4 because 
they are not JAK2 mutation–specific.
Ruxolitinib is the first-in-class JAK1/JAK2 inhib-
itor commercially available for the treatment of MF. 
Ruxolitinib ameliorates inflammation and proliferation, 
which leads to clinically relevant control of splenomeg-
aly and symptoms in the majority of patients with MF, 
which may result in prolonged survival.5-8 Nonetheless, 
long-term studies have demonstrated a lack of response 
in some patients and loss of response in the majority 
of patients.9 Some patients may not tolerate ruxolitinib 
because of therapy-related anemia, thrombocytopenia, 
or nonhematologic adverse events, in particular, infec-
tious complications.10-12 Consequently, ruxolitinib is 
discontinued by most patients during the first 5  years 
of treatment. In the registration-enabling Controlled 
Myelofibrosis Study With Oral JAK Inhibitor Treatment 
(COMFORT)-I and COMFORT-II studies, which 
enrolled only intermediate-2–risk and high-risk patients, 
the rate of treatment discontinuation was approximately 
50% at 3 years and 75% at 5 years; whereas the expand-
ed-access JAK Inhibitor Ruxolitinib in Myelofibrosis 
Patients (JUMP) study, which also included interme-
diate-1–risk patients, reported a discontinuation rate 
of 35% after 3 years.5,7,8 The outcome of patients who 
failed ruxolitinib within the phase 1/2 trial reportedly 
was poor (median survival, 14 months). Outcomes were 
particularly poor in patients who had molecular clonal 
evolution and thrombocytopenia.13 A second study 
of 64 patients treated in a real-life comparison con-
firmed that responses to salvage treatments are rare.14 
Understanding that the outcome after ruxolitinib is 
important for identifying patients who may benefit from 
specific interventions, such as allogeneic stem cell trans-
plantation,15 second-generation JAK inhibitors,16-18 
drugs with alternative mechanisms of action,19,20 or in-
vestigational agents in combination with ruxolitinib.21
Here, we report the outcome of 218 patients 
after ruxolitinib. Our objective was to investigate: 
1) the correlations between preruxolitinib disease char-
acteristics and the probability of drug discontinuation, 
2) the effects of reasons for discontinuation and disease 
status at the time of discontinuation on survival, and 
3) the influence of salvage therapies on outcome after 
ruxolitinib.
MATERIALS AND METHODS
Study Cohort and Treatment
A multicenter, observational, retrospective study of 
patients who had MF treated with ruxolitinib was con-
ducted in 20 European hematology centers. Participants 
were enrolled into the JUMP trial (clinicaltrials.gov iden-
tifier NCT01493414) or were treated off-study accord-
ing to standard clinical practice, as previously described.22 
Data were extracted from an electronic database, which 
included consecutive patients who were treated with rux-
olitinib from June 2011. All treatments for MF, baseline 
clinical/laboratory features, and outcome measures (includ-
ing evolution into blast phase [BP], death, and spleen re-
sponses) were recorded. Diagnoses of primary MF (PMF) 
and postpolycythemia vera (PPV)/postessential thrombo-
cythemia (PET) MF were made according to World Health 
Organization 2008 criteria or International Working Group 
on Myelofibrosis Research and Treatment (IWG-MRT) cri-
teria, respectively.23,24 All patients who received treatment 
with ruxolitinib in the current analysis were in chronic 
phase (peripheral and bone marrow blast cells <10%).
Risk category was assessed at the time patients started 
on ruxolitinib according to the Dynamic International 
Prognostic Score System (DIPSS).25 Histologic exam-
ination was performed at local institutions; fibrosis was 
graded according to the European Consensus Grading 
System. Unfavorable karyotype was categorized as previ-
ously described.26 Diagnosis of BP was made according 
to World Health Organization criteria, with a 20% bone 
marrow or peripheral blood blast threshold for diagno-
sis.24 The burden of MF-related symptoms was assessed 
using the 10-item Myeloproliferative Neoplasm Symptom 
Assessment Form Total Symptom Score (MPN10-TSS).27
Spleen responses were assessed according to 2013 
IWG-MRT/European LeukemiaNet (ELN) criteria.28 
We acknowledge that, in many clinical situations, pa-
tients who have MF without an IWG-MRT/ELN-defined 
spleen response still may have a clinical benefit on spleno-
megaly from ruxolitinib (ie, smaller than at baseline), but 
we decided to use strict definitions in our analyses. The 
lack of a spleen response identified patients who never 
achieved a spleen response, whereas a loss of response was 
defined as any increase in spleen size compared with the 
patient’s best recorded response. Specifically, at the time 
patients lost a spleen response, the spleen still may have 
been smaller than it was at baseline.
All adverse events were defined and graded 
according to Common Terminology Criteria for Adverse 
Events, version 4.0. Ruxolitinib-related and ruxolitinib- 
unrelated adverse events were considered separately. 
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The reasons for discontinuation and their causal rela-
tionship with the drug were assigned according to the 
judgment of the treating hematologist. We are aware 
that, in this respect, distinguishing MF-associated from 
ruxolitinib-induced myelosuppression may be particu-
larly challenging. Here, ruxolitinib discontinuation was 
attributed to drug-related anemia and/or thrombocyto-
penia when cytopenias improved within 3 months after 
ruxolitinib was discontinued and/or could not be ascribed 
to other evident causes (ie, bleedings, comorbidities, BP 
transformation). With the objective of distinguishing 
ruxolitinib-induced hematologic toxicity from cytopenias 
caused by disease progression, if ruxolitinib discontin-
uation was induced by anemia/thrombocytopenia that 
resulted in a frank evolution to BP within 3 months after 
stopping the drug, then, at best, the cause of discontinu-
ation was considered to be BP; conversely, when anemia/
thrombocytopenia was concomitant to a lack or loss of 
response, then the cause for discontinuing ruxolitinib was 
considered to be a lack or loss of response. Erythrocyte 
transfusion dependency was defined according to IWG-
MRT/ELN criteria.28
Comorbidities were recorded at the time of rux-
olitinib start and classified according to the Charlson 
comorbidity index (CCI).29 This study was approved 
by the Institutional Review Board of each institution 
and was conducted according to the Declaration of 
Helsinki.
Statistical Analysis
Continuous variables are expressed as medians and ranges 
or means and standard deviations, whereas categorical vari-
ables are presented as frequencies and percentages. We used 
the Wilcoxon-Mann-Whitney rank-sum test or the t test for 
comparisons between groups, and associations between cat-
egorical variables (2-way tables) were tested using the Fisher 
exact test or the chi-square test, as appropriate. Continuous 
and categorical variables at ruxolitinib start and discontinu-
ation were compared using the Wilcoxon signed-rank test 
and the McNemar test, respectively.
Risk factors for ruxolitinib discontinuation and 
prognostic factors for survival were identified using uni-
variate and multivariable Cox proportional hazards model. 
Multivariable Cox analysis was conducted on variables 
with P values <.10 at univariate analysis. To avoid the 
issue of multicollinearity and to remove highly correlated 
predictors from the model, collinearity among variables 
was detected using the Pearson correlation test. Variables 
that were associated with other factors in univariate anal-
ysis were excluded from the multivariable analysis.
Survival analyses were performed using Kaplan-
Meier curves, and differences were evaluated using the 
log-rank test. Overall survival was calculated from the 
date of ruxolitinib discontinuation to either death or last 
contact. Tests were 2-sided, and P values <.05 were con-
sidered significant. Analyses were performed with using 
STATA software version 15 (StataCorp).
RESULTS
Study Cohort and Risk Factors Associated  
With Ruxolitinib Discontinuation
From 2011 to October 2018, in total, 524 patients with 
PMF (n = 277; 52.9%), PPV-MF (27.8%), or PET-MF 
(19.3%) were treated with ruxolitinib in participat-
ing centers. At time patients started on ruxolitinib, the 
median age was 68 years (range, 24-88 years), and 59% 
were men. DIPSS distribution was intermediate-1 risk 
(52.4%), intermediate-2 risk (40.8%), and high risk 
(6.8%). In total, 52 (9.9%) and 126 (24%) patients had 
platelet counts <100 ×109/L or were erythrocyte transfu-
sion-dependent, respectively. The spleen was palpable at 
<5 cm, at between 5 cm and 10 cm, and at >10 cm below 
the left costal margin in 9.4%, 37.2%, and 53.4% of 
patients, respectively. The median MPN10-TSS score was 
20 (range, 5-100). Driver mutation distribution was as 
follows: JAK2 V617F (82.9%), CALR mutations (11%), 
and MPL W515K/L (1.2%); and 4.9% of patients were 
triple-negative. Karyotype was abnormal in 93 of 348 
(26.7%) evaluable patients. In 26 patients (7.4%) an 
unfavorable karyotype was detected, specifically: trisomy 
8, complex, del7, del5, inv3, and 11q23 rearrangement.
After a median follow-up from ruxolitinib start of 
37  months, 268 patients (51.1%) discontinued ruxoli-
tinib, with a median drug exposure of 17.5 months (range, 
1-81.7 months) (Fig. 1). The percentage of patients who 
discontinued ruxolitinib was 22.2%, 32.4%, and 40.8% at 
1 year, 2 years, and 3 years, respectively. The overall ruxoli-
tinib discontinuation rate was 19.6 per 100 patient-years. 
A comparison of clinical and laboratory features at the start 
and end of ruxolitinib treatment showed that patients had 
significantly lower platelet counts and hemoglobin levels, 
but higher leukocytes and peripheral blast cell counts, at 
the time of ruxolitinib discontinuation. In addition, spleen 
length and symptom burden were significantly lower at 
discontinuation (Table 1).
In univariate analysis, PMF diagnosis, intermedi-
ate-2/high DIPSS risk, transfusion-dependent anemia, 
platelet count <100  ×109/L, peripheral blasts ≥1%, 
splenomegaly ≥15 cm below the left costal margin, the 
presence of comorbidities (CCI  ≥  2), and unfavorable 
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karyotype were significantly associated with a greater 
probability of drug discontinuation. After multivariable 
analysis, intermediate-2/high DIPSS risk, transfusion de-
pendency, platelet count <100 ×109/L, and unfavorable 
karyotype remained significant (Fig. 2). In addition, we 
conducted a subanalysis after patient stratification into 3 
categories according to the percentage of peripheral blasts: 
no peripheral blasts (61.2% of patients), from 1% to 5% 
peripheral blasts (34.9%) and from 6% to 9% peripheral 
blasts (3.9%). The probability of ruxolitinib discontinua-
tion at 2 years was 28.6%, 43.5% and 61.5% in patients 
with no peripheral blasts, 1% to 5% peripheral blasts, and 
6% to 9% peripheral blasts, respectively (P = .005).
Outcome According to the Reason for 
Ruxolitinib Discontinuation
Fifty patients (18.7%) died while taking ruxolitinib because 
of MF (34%), infections (24%), bleedings/thrombosis 
(12%), secondary neoplasms (10%), or other unrelated 
causes (20%). In these 50 patients, the median ruxolitinib 
exposure was 22.3  months (range, 1.0-81.7  months). 
Notably, BP was always preceded by or coincided with the 
discontinuation of ruxolitinib; therefore, no patient died 
from BP-MPN or secondary AML during therapy. Follow-up 
data are available for 218 patients who were observed for a 
total of 286.8 patient-years after ruxolitinib discontinuation.
The reason for ruxolitinib discontinuation was 
the lack or loss of a spleen response in 50 (22.9%) and 
26 (11.9%) patients, respectively. Fifty-one patients 
(23.4%) discontinued because of progression to BP. 
In total, 60 patients (27.5%) discontinued because 
of ruxolitinib-related adverse events, namely: anemia 
(n =  23; 10.5%), thrombocytopenia (n =  15; 6.9%), 
infections (n = 20; 9.2%), and neurologic side effects 
(n = 2; 0.9%). An additional 20 patients (9.2%) discon-
tinued because of ruxolitinib-unrelated adverse events, 
namely: second solid neoplasms (n  =  10), thrombo-
sis (n = 7), heart failure (n = 2), and pleural effusion 
Figure 1. The disposition of all patients is illustrated. Patients received conventional and novel therapies either alone or in 
combination. Eighteen patients received with both conventional and novel agents. Twenty-six patients also underwent allogeneic 
stem cell transplantation after receiving conventional therapies. Overall, 54 patients received uniquely conventional medical therapy. 
The direction of the arrows between conventional and novel therapies indicates which type of therapy was received first. ESA 
indicates erythropoietin-stimulating agents.
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(n = 1). Eleven patients (5.1%) patients stopped ruxoli-
tinib while in response to undergo allogeneic stem cell 
transplantation.
The median cumulative ruxolitinib dose was signifi-
cantly higher in patients who discontinued because of the 
lack or loss of a spleen response, with 44.7% of patients 
receiving a median daily dose ≥15  mg twice daily (vs 
18.4% of patients who discontinued because of ruxoli-
tinib-related hematologic toxicity; P = .006); notably, the 
median drug exposure was comparable in the 2 groups 
(16.5 vs 17.5 months, respectively; P = .14). More spe-
cifically, we observed that the cumulative ruxolitinib dose 
was comparable in patients who discontinued ruxolitinib 
because of thrombocytopenia or anemia (P = .06).
The median survival after ruxolitinib discontinua-
tion for the entire cohort of 218 patients was 13.2 months 
(95% CI, 8.0-22.7 months). The median survival was of 
32.4, 27.9, 13.2, 3.9, and 3.6 months for patients who dis-
continued because of the loss of a spleen response, the lack 
of a spleen response, ruxolitinib-related adverse events, 
BP, and ruxolitinib-unrelated adverse events, respectively. 
Overall, a significant difference in survival between the 
groups was detected (log-rank test; P < .001). This differ-
ence was caused in particular by those who developed BP 
and those who stopped ruxolitinib for drug-unrelated ad-
verse events, who had the worst outcomes, whereas over-
all survival was comparable in patients who discontinued 
because of the lack or loss of a response or ruxolitinib-re-
lated adverse events (Fig. 3). The death rates among pa-
tients who discontinued because of BP, drug-unrelated 
adverse events, ruxolitinib-related adverse events, the 
lack of a spleen response, or the loss of a spleen response 
were 10.5 per 100 patient-months (95% CI, 7.9-14.1 per 
100 patient-months), 6.8 per 100 patient-months (95% 
CI, 4.0-11.7 per 100 patient-months), 3.2 per 100 pa-
tient-months (95% CI, 2.3-4.5 per 100 patient-months), 
2.9 per 100 patient-months (95% CI, 2.1-4.3 per 100 
patient-months), and 2.1 per 100 patient-months (95% 
CI, 1.1-3.8 per 100 patient-months), respectively.
Outcome of Patients Who Discontinued in 
Chronic Phase
In total, 167 patients discontinued ruxolitinib while in 
chronic phase and had a median survival after discontinu-
ation of 27.5 months. Causes of death in this cohort in-
cluded progression of MF (35.2%), infections (12.5%), 
bleedings/thrombosis (12.5%), second solid neoplasia 
(11.4%), heart disease (5.7%), and other MF-unrelated 
causes (21.6%). Among clinical and laboratory parame-
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showed that hemoglobin <10 g/dL (P = .03; hazard ratio 
[HR], 1.70; 95% CI, 1.05-2.76), circulating blast count 
≥1% (P  =  .02; HR, 1.72; 95% CI, 1.09-2.71), and 
platelet count <100 ×109/L (P =  .04; HR, 1.63; 95% 
CI, 1.04-2.42) correlated significantly with worse sur-
vival. Multivariable analysis confirmed that hemoglobin 
<10 g/dL (P = .01; HR, 1.92; 95% CI, 1.19-3.11) and 
circulating blast count ≥1% (P = .01; HR, 1.75; 95% CI, 
1.11-2.74) at the time of ruxolitinib discontinuation 
correlated with worse survival.
In total, 111 patients (66.5%) received at least 1 
additional line of therapy after ruxolitinib discontinua-
tion. Among the 56 patients who did not receive further 
treatment, 46 (82.1%) were considered unfit to receive 
further therapy because of: poor performance and/or 
health status (60.9%), cytopenias and/or recurrent infec-
tions (30.4%), and co-occurrence of significant adverse 
events (heart failure, thrombosis; 8.7%). In 3 patients 
(5.4%), the diagnosis of a second malignancy prevented 
salvage treatment after ruxolitinib. In 7 patients (12.5%), 
no available drug was considered potentially effective 
by the treating hematologist. Overall, patients who did 
not receive further therapy after ruxolitinib discontinua-
tion were characterized by older age (mean age, 66.2 vs 
72.2 years; P <  .001) and higher CCI (mean CCI, 1.5 
vs 1.0; P = .02) compared with patients who did receive 
further therapy. In addition, patients who discontinued 
because of a lack or loss of response were treated more 
frequently compared with those who discontinued 
because of ruxolitinib-related or ruxolitinib-unrelated 
adverse events (P < .001) (see Supporting Table 1).
Figure 2. Univariate Cox analysis is illustrated of the baseline risk factors that were predictive for discontinuation of ruxolitinib 
(RUX). Variables with P values <.10 in univariate analysis were considered for multivariable analysis, and collinearity among variables 
was detected by using the Pearson correlation test. Because the ruxolitinib starting dose was based on the platelet count, this 
variable was not included in the analysis. In addition, peripheral blasts from 6% to 9% were associated with a greater probability of 
ruxolitinib discontinuation in univariate analysis (hazard ratio, 1.84; 95% CI, 1.01-3.36; P = .049). Peripheral blasts (using cutoff levels 
of both ≥1% and 6%-9%) were correlated with the Dynamic International Prognostic Score System (DIPSS) (Pearson correlation 
test) and were not included in multivariable analysis. Four variables (indicate in red) remained significantly associated with 
ruxolitinib discontinuation after multivariable analysis. The Harrell C concordance index was 0.75, and the Gronnesby and Borgan 
goodness-of-fit test reported a P value = .9. BLCM indicates below the left costal margin; PMF, primary myelofibrosis; PPV/PET-MF, 
postpolycythemia vera/postessential thrombocythemia myelofibrosis.
Figure 3. Overall survival is illustrated according to the 
reason for ruxolitinib (RUX) discontinuation. The 11 patients 
who discontinued ruxolitinib to undergo allogeneic stem cell 
transplantation while in response were excluded from this 
survival analysis. The P value reported on the figure results 
from the log-rank test for the overall difference between all 
Kaplan-Meier curves. Pairwise log-rank tests between all curves 
were conducted and confirmed that patients who discontinued 
because of a lack or loss of response had statistically 
comparable survival distributions compared with those who 
discontinued because of ruxolitinib-related adverse events 
(AEs) (P = .93 and P = .34, respectively) and that the patients 
who had significantly worse survival that had a major effect on 
the overall difference (P < .001) were those who discontinued 
because of ruxolitinib-unrelated events and blast phase.
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Overall, patients who were treated after ruxoli-
tinib discontinuation had significantly better outcomes 
than those who were not treated after discontinuing the 
drug (median survival, 34.8 vs 3.6 months, respectively; 
P < .001). The median time from ruxolitinib discontinu-
ation to the start of a salvage therapy was 1 month (range, 
0-45 months).
The treatments received after ruxolitinib discontin-
uation are summarized in Figure 1. Overall, 31 patients 
received salvage therapies, including ruxolitinib rechal-
lenge and/or investigational agents, whereas 54 patients 
received exclusively conventional therapies. More spe-
cifically, 11 patients had a ruxolitinib rechallenge after a 
median of 16  months from ruxolitinib discontinuation 
(range, 3-70 months). The causes of discontinuation in 
these 11 patients were the lack or loss of a spleen response 
(n = 6), infectious events (n = 2), anemia (n = 1), and 
ruxolitinib-unrelated adverse events (pleural effusion and 
heart failure). Ruxolitinib rechallenge was used as the first 
salvage option or after another line of treatment in 3 and 
8 patients, respectively. At rechallenge, the ruxolitinib 
dose was the same as before the discontinuation in all but 
1 patient who rechallenged ruxolitinib at a lower dose.
Causes of discontinuation and disease burden at 
discontinuation of ruxolitinib (specifically, DIPSS distri-
bution, spleen length, TSS, and hemoglobin/leukocyte/
platelet/peripheral blast values) were comparable between 
patients who received conventional therapies only and 
patients those were received ruxolitinib rechallenge and/
or investigational agents. Overall survival seemed to be 
longer in this latter cohort (40.5 vs 28.9 months; P = .04) 
(Fig. 4).
Outcome of Patients Who Discontinued 
Because of Transformation Into BP-MPN
Overall, 51 patients (23.4%) patients discontinued rux-
olitinib because of progression to BP-MPN. Twenty-
eight patients (54.9%) received a salvage treatment, 
specifically: hydroxyurea (n  =  14), hypomethylating 
agents (azacytidine/decitabine; n  =  7), chemother-
apy (n  =  6), and allogeneic stem cell transplantation 
(n = 5).
After a median of 3.2 months from ruxolitinib dis-
continuation, 46 patients died (90.2%). The median sur-
vival was significantly longer for patients who received 
therapy after ruxolitinib (7.9 months vs 2 months in un-
treated patients; P = .005). The type of therapy received 
after ruxolitinib did not significantly influence survival 
(P =  .17). In multivariate analysis, only anemia (hemo-
globin < 10 g/dL) at ruxolitinib discontinuation was cor-
related significantly with worse survival.
DISCUSSION
The management of patients with MF after ruxolitinib 
represents a major challenge in real-life clinical practice. 
Here, we observed that higher DIPSS risk category, lower 
platelet count, unfavorable karyotype, and erythrocyte 
transfusion dependency at ruxolitinib start were associ-
ated with a greater probability of drug discontinuation. 
These parameters correlated with those already related to 
inferior survival in the DIPSS-plus score; specifically, the 
role of cytogenetics in predicting ruxolitinib discontinu-
ation supports the importance of karyotype in the prog-
nostic assessment of patients with MF. In addition, the 
association of an elevated circulating blast cell count with 
increased treatment failure is in agreement with recent 
data suggesting its negative effect on survival.30
Importantly, we noticed that the 3 top clinical 
reasons for stopping ruxolitinib in patients with MF in 
chronic phase inadequately controlled splenomegaly 
(including the lack or loss of a spleen response; 34.8%), 
anemia/thrombocytopenia (17.4%), and infectious events 
(9.2%). First, failure to achieve or maintain a significant 
spleen response was the main cause of discontinuation, 
probably because ruxolitinib is initiated in most patients 
to target this specific clinical need. However, we observed 
Figure 4. The overall survival of patients who discontinued 
ruxolitinib in chronic phase is illustrated according to the type of 
salvage treatment they received after discontinuation. Patients 
were not randomized between the 2 groups. Novel agents 
include ruxolitinib rechallenge, investigational JAK2 inhibitors, 
and investigational non-JAK2 inhibitors. Conventional therapies 
include hydroxyurea, danazol, erythropoiesis-stimulating agents, 
corticosteroids, and splenectomy. The 26 patients who 
underwent allogeneic stem cell transplantation were excluded 
from this survival analysis. The 18 patients who received both 
conventional and novel therapies were included only in the 
“novel agents” cohort.
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a counterintuitive decrease in baseline symptoms and 
splenomegaly at ruxolitinib discontinuation, indicat-
ing that ruxolitinib had some degree of efficacy, even in 
patients who finally discontinued the drug. Second, almost 
20% of patients discontinued because of hematologic 
toxicity. This result matches with the greater frequency 
of anemia and thrombocytopenia that we detected at 
the time of ruxolitinib discontinuation. Third, the cur-
rent study points out that infections may lead to discon-
tinuation in a substantial fraction of ruxolitinib-treated 
patients, reinforcing the recommendation for close infec-
tious monitoring before and during therapy.31 Finally, we 
observed that the cumulative ruxolitinib dose was signifi-
cantly higher in patients who discontinued because of the 
lack or loss of a spleen response compared with those who 
discontinued because of ruxolitinib-related hematologic 
toxicity but was comparable in those who discontinued 
because of anemia or thrombocytopenia.
This finding reflects the adherence of treating hema-
tologists to prescribing information, according to which the 
ruxolitinib dose should be reduced in case of thrombocy-
topenia.32 Conversely, we observed that both anemia and 
thrombocytopenia comparably triggered reductions of the 
ruxolitinib dose. This observation probably reflects that ane-
mia is managed in real life with great caution and provides 
new insights into the practical management of ruxolitinib.
The main predictor of outcome after ruxolitinib, as 
expected, was disease status (chronic phase vs BP). Indeed, 
among patients in chronic phase, the median overall sur-
vival exceeded 24 months and was almost 35 months if at 
least 1 salvage therapy was attempted. In addition, the use 
of investigational agents and/or ruxolitinib rechallenge 
possibly may be associated with improved survival com-
pared with conventional treatments, excluding allogeneic 
stem cell transplantation, raising the median survival 
beyond 40  months. This comparison has well known 
limitations (mainly, its retrospective and nonrandomized 
nature, the number of patients involved, the possible role 
of additional factors, such as willingness to participate in 
a clinical trial, and the heterogeneity of therapeutic ap-
proaches). Nevertheless, this may support the finding that 
participation in clinical trials after ruxolitinib discontinu-
ation has the potential to significantly improve outcome. 
From a practical point of view, even with no innovative 
clinical trials available, ruxolitinib rechallenge may be a 
valuable therapeutic option in routine clinical practice 
and previously was associated with significant clinical 
responses.33 Also, we observed that survival was signifi-
cantly worse in patients who did not receive any treat-
ment after ruxolitinib, suggesting indeed that all possible 
patients should receive therapy after ruxolitinib. Finally, 
although patients who lack or lose a spleen response are 
clinically (and probably biologically) heterogeneous, we 
unexpectedly noted that survival was comparable in these 
2 cohorts. This observation may further highlight that 
patients who do not achieve official IWG-MRT responses 
may derive benefit from ruxolitinib.
Also, we did not detect any significant difference in 
survival between patients who discontinued ruxolitinib 
because of the lack or loss of a response and those who 
discontinued because of drug-related toxicity. Conversely, 
patients who experienced ruxolitinib-unrelated adverse 
events had significantly poorer projected outcomes, mainly 
because of the detrimental effect of second solid neopla-
sia. Overall, these observations may indicate that ruxoli-
tinib-induced toxicity is not predictive of inferior survival, 
as noted previously for anemia during ruxolitinib therapy. 
In addition, these findings highlight the importance of 
strictly monitoring ruxolitinib-exposed patients in onco-
logic practice.34,35 However, despite the absence of statisti-
cal significance, the difference in median survival between 
patients who lacked or lost a spleen response and those who 
had ruxolitinib-related adverse events may be clinically rel-
evant (approximately 30 vs 13.2 months) and may have 
been caused in part by the lower likelihood of receiving fur-
ther treatments in patients who discontinued ruxolitinib 
because of cytopenias or infections. From a clinical point 
of view, the latter patients are certainly the most vulner-
able, with extremely limited therapeutic possibilities after 
ruxolitinib, and thus should require special attention and 
research.
This study does not provide the dynamics of non-
driver mutations, which are not recommended in a real-life 
context but were previously identified as very informative,13 
but we did identify clinical and laboratory features that can 
easily be assessed in everyday clinical practice and may be 
associated with ruxolitinib discontinuation and outcome.
Despite the well known limitations inherent in ret-
rospective studies, the objective of the current analysis was 
to provide valuable information not only about the risk 
factors for ruxolitinib discontinuation (which were found 
to correspond to higher risk disease) but also about the 
reasons for discontinuation and long-term outcomes after 
discontinuation. The latter data are extremely relevant to 
guide clinical practice and could hardly be extrapolated 
from further analyses of prospective studies. Overall, we 
observed that outcomes were extremely poor for patients 
who had MF in BP regardless of treatment, whereas, for 
those in chronic phase, receiving a salvage therapy and 
particularly entering a clinical trial possibly may improve 
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survival. Overall, the outcome of patients with MF after 
ruxolitinib discontinuation remains dismal, urging the 
need for new treatment strategies.
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